Context: Risk alleles of the fat mass-and obesity-associated gene (FTO) are related not only to increased body mass index (BMI) values but also to mortality. It was speculated that cellular effects of the FTO gene affect most organs, especially their ability to maintain or regenerate proper function when afflicted by various diseases. FTO is highly expressed in the hypothalamus and also in the pituitary gland. The decrease in growth hormone (GH) secretion is known to cause a decrease in lean body mass in older subjects. Objective: We hypothesized an association of rs9926289 with insulin-like growth factor (IGF)-I. Design and setting: Cross-sectional data from the Study of Health in Pomerania, a population-based study in the northeastern part of Germany, were used. Participants: For the final analyses, 3882 subjects aged 20-79 years were available. Main outcome measures: Continuous IGF-I, low IGF-I according to clinically meaningful age-and gender-specific reference values, and BMI were used as outcome measures. Results: Over all age groups, a statistically significant relationship between FTO and IGF-I was found. In subjects younger than 55 years of age, homozygous carriers of the FTO risk allele exhibited lower serum IGF-I levels adjusted for 5-year age groups, gender and IGF-I binding protein 3 levels (linear regression, coefficient ± s.e. for FTO AA genotype:À8.6 ± 2.8; P ¼ 0.002). Further adjustments for obesity and diabetes did not suspend this association (coefficient:-7.8; P ¼ 0.005). As expected, the FTO AA genotype effect on BMI was reduced from 0.76 to 0.62 kg m À2 by including IGF-I. No relationship between FTO and IGF-I levels was found in subjects aged 55 years or older (À2.7±2.4; P ¼ 0.260 for FTO AA genotype adjusted for age, gender and IGF-I binding protein 3 levels). Conclusion: We propose that the GHFIGF-I axis is a mediator for the relationship between FTO and BMI.
Introduction
The obesity epidemic is a growing health problem in many countries of the world because obesity and overweight are major risk factors for hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, gallstones, fatty liver disease and some cancer entities, to name a few. Obesity is defined as a body mass index (BMI) X30 kg m
À2
, and overweight as a BMI X25 kg m
. BMI heritability is estimated at B60-70%. 1 Common variants in the first intron of the fat mass-and obesity-associated gene (FTO) are related to increased BMI and in turn to type 2 diabetes mellitus in genome-wide association studies. [2] [3] [4] [5] [6] Of all genetic factors contributing to polygenic obesity identified in genome-wide association studies, the effects of FTO variants are most pronounced. When compared with subjects carrying no copy of the risk allele, individuals homozygous for the risk allele had a 1.67-fold increased odds ratio for obesity, and mean body weights differed by almost 3 kg. 3 The relationship between FTO risk alleles and BMI is due to an increase in fat mass; 3 however, the precise mechanisms by which risk alleles of FTO precipitate increased BMI have remained elusive. In manFpredominately in childrenFincreased energy intake [7] [8] [9] and decreased satiety 9 were suggested to link FTO risk alleles with obesity, findings, however, not unanimously reported. 10 In contrast, reduced energy expenditure and physical activity were not associated with FTO genotypes. 7, 8, 10, 11 Nevertheless, physical activity modified the degree of obesity achieved in the context of the risk allele of FTO.
12,13
These pathomechanisms in man differed from mice lacking the Fto gene.
14 In this animal model, variant energy expenditure is part of a main phenotype. In such mice, a significant reduction in adipose tissue, lean body mass and postnatal growth retardation were observed. 14 Loss of Fto results obviously in increased energy expenditure and systemic sympathetic activation, despite relative hyperphagia and spontaneous locomotor activity. 14 Another type of mouse model harbouring a deficient Fto protein with a missense mutation supported the increased energy spending. 15 The ubiquitously occurring Fto is most abundantly expressed in the hypothalamus and the pituitary gland, 3, 14, [16] [17] [18] a plausible brain region, as most obesity genes identified by genome-wide association are expressed here. 19 In the arcuate nucleus of the hypothalamus, rodent
Fto mRNA levels have been reported to be regulated by feeding and fasting. 16, 18, 20 Despite these attractive animal models, comprehensive information of the role of FTOF especially in manFis scarce. In this study, we examined the effects of the risk allele of FTO on different indexes of fatness in the Study of Health in Pomerania (SHIP), 21 a population-based study in northeastern Germany, a region with high prevalence of overweight and obesity. We found that the effect of FTO on BMI gradually diminished in men and women with advancing age, an observation shared by others. 3, [22] [23] [24] Jacobsson et al.
found no association between FTO and BMI when they analysed a cohort of 1115 men, who were repeatedly examined each decade starting from the age of 50 years. 23 Similarly, Hardy et al. reported that the association between FTO and BMI increased during childhood and adolescence, peaked at around 20 years, diminished gradually with advanced age and levelled off by the age of 53 years.
22
Given the age-dependent reduction of growth hormone (GH) and insulin-like growth factor-I (IGF-I), 25 we hypothesized that the risk alleles of FTO were associated with the GH-IGF-I axis. Biological evidence is based on the abundant expression of FTO in the hypothalamus and pituitary gland, both key organs for the GH-IGF-I axis and also for weight control. Circulating IGF-I is predominantly synthesized in the liver on stimulation with GH and mediates most of GH's endocrine actions, including regulation of cell proliferation, protein synthesis, carbohydrate homeostasis, bone metabolism and the modulation of body composition. [26] [27] [28] In this study, we suggest that IGF-I partly mediates the association between the FTO risk allele and BMI.
Materials and methods
Study population SHIP is a cross-sectional population-based health survey in West Pomerania, a region in the northeastern part of Germany. The detailed objectives and study design have been published elsewhere. 21 In brief, from a total population of 212 157 inhabitants, a sample of 6267 eligible subjects was drawn on the basis of the official population registry. Inclusion criteria comprised of German citizenship and principal residency in the study area. The selection strategy aimed at generating 12 equal 5-year age strata for both genders each, representing an age range from 20 to 79 years. Finally, SHIP comprised of 4310 participants, corresponding to a final participation proportion of 68.8%. Data collection started in October 1997 and was completed in May 2001. The study protocol was reviewed by a board of independent scientists and approved by the Ethics Committee of the University of Greifswald. All participants gave a written informed consent. Sociodemographic and medical characteristics were assessed by computer-assisted personal interviews. Diabetes mellitus was defined as a self-reported history of diabetes that was diagnosed by a physician. In preliminary analyses, pregnant women (n ¼ 17) and subjects with cancer (n ¼ 51) were excluded. These exclusion criteria produced similar results, and all models presented are without any exclusion criterion. Height and weight were measured for the calculation of BMI. Overweight was defined as BMI of X25 kg m
À2
and obesity as BMI of X30 kg m
. Waist and hip circumferences were measured by trained study nurses.
Hormone analyses GH is released in a pulsatile manner and adequate examinations of GH secretion require repeated blood samplings, procedures that are highly unsuitable for epidemiological surveys. Determination of serum IGF-I concentration is widely used as a stable biomarker for the long-term status of GH secretion in clinical practice. Non-fasting blood samples were drawn from the cubital vein in the supine position. The samples were stored at À80 1C until assay. In September 2005, serum IGF-I and IGF binding protein 3 (IGFBP3) were determined by automated two-site chemiluminescence immunoassays (Nichols Advantage; Nichols Institute Diagnostica GmbH, Bad Vilbel, Germany). In both assays, biotin-labelled monoclonal antibodies were used as capture, and in a second step, acridinium-ester-labelled , the intra and interassay imprecision rates within the range of 227-2703 ng ml À1 were 5.8 and 11%, respectively. The assay reference standard was analytically prepared with glycosylated recombinant human IGFBP3. Only one lot of reagents was used for all IGFBP3 measurements. For IGF-I concentration, a diurnal variation was reported. 29 Values from midnight until 0400 h were slightly lower. This period, however, does not meet for SHIP.
In additional analyses, we used clinically meaningful categories of 'low', 'normal' and 'high' serum IGF-I levels on the basis of reference values for clinical purposes derived from healthy SHIP participants. 30 These reference values were assayed with the same method as described above.
On the basis of quantile regression and the resulting genderand age-specific reference ranges, 30 the highest 2.5% was considered to be 'high', whereas the lowest 2.5% was considered to be 'low'.
Genotyping
We genotyped rs9926289, a polymorphism 24-bp adjacent to rs9939609, the single-nucleotide polymorphism analysed in the first study by Frayling et.al 3 HapMap analyses revealed that rs9926289 and rs9939609 are completely linked. Furthermore, rs9926280 was identified as another variant strongly associated with BMI in this paper. 3 The locus comprising rs9926289 was amplified using primers 5 0 -GAGGTTGCTCTGACGGCTGTAG-AGGATAGACCATAG-3 0 and 5 0 -GCCAGGATAGTTTCGATCTATTGACCTCATG-3 0 . The PCR amplicon of 881 bp was digested for the variant A-allele into two fragments of 551 and 330 bp with the restriction enzyme XbaI (Fermentas, Str Leon-Rot, Germany), whereas the wild-type G-allele remained unrestricted. In all, 200 random samples were regenotyped and we observed only one divergent result (0.05%).
Statistical analysis
Data on quantitative characteristics are expressed as means±s.d. or s.e., as indicated. Data on qualitative characteristics are expressed as percentage values or absolute numbers as noted. Multivariable analyses of a continuous outcome were performed by linear models. BMI was routinely treated as a linear value. However, BMI is not normally distributed. Analyses of log-transformed BMI values produced essentially the same results. Multivariable analyses of a binary outcome were performed by logistic regression. Odds ratio and its 95% confidence interval are given. We used the criterion of change in the coefficient of interest (for example, FTO) to estimate the effect of a confounder or a putative mediator on the relationship analysed (for example, between FTO and BMI). A substantial change was considered present if inclusion in the model led to a X10% change in the coefficient of interest. A value of Po0.05 was considered statistically significant. Analyses were performed with STATA/SE software, version 10.1 (StataCorp LP, College Station, TX, USA). Smoothed plots were used to show age and genotype dependencies in more detail. They were generated with the STATA command 'lowess'. For the amount of smoothing, we chose a bandwidth ¼ 0.8, indicating that 80% of the data are used in smoothing each point.
Results
Out of the 4310 participants of SHIP, 48 dissented to genetic analyses and no DNA was available from 81 individuals. Genotyping failed in 113 individuals (call rate 97.3%). Owing to missing IGF-I or IGFBP3 levels, an additional 178 individuals were excluded. For a further eight individuals, no BMI could be calculated. Out of the remaining 3882 individuals available for the final analyses, 1359 (35.0%) subjects were carriers of the rs9926289 GG allele, 1851 (47.7%) were heterozygous and 672 (17.3%) subjects carried the AA genotype. This distribution of rs9926289 was in accordance with the Hardy-Weinberg equilibrium (P40.200) and mirrored the genotype distribution of rs9939609 in other studies. 3 Next, we analysed BMI, weight, waist and hip circumferences and waist-to-hip ratio of all the participants of the SHIP study, adjusted for gender and for 5-year age groups (Table 1a) . No measures of fatness were associated with the risk allele of FTO, either in an additive model or in a recessive one (Table 1a) .
When we analysed the age-dependent BMI and weight patterns, we noticed that mean BMI values levelled off and mean weight exhibited a turning point at around 55 years (Figures 1a and b) . As indicated in Introduction, such agedependent effects of FTO were observed by others [22] [23] [24] and, coincidentally, the limit beyond which FTO had only a weak or absent effect on BMI was calculated at 53 years by Hardy et al. 22 Subsequently, we chose 55 years of age as cutoff point.
For both age strata, the genotype distribution was in accordance with Hardy-Weinberg equilibrium (P40.200). We questioned the biological rationale for this agedependent effect, that is, the risk allele of FTO had its most pronounced and dynamic effect in periods when weight gain was the highest. Potentially, this life-course variation was indicative of secretory patterns of the GH-IGF-I axis. Figure 2 illustrates this age-dependent pattern for IGF-I. It is noteworthy that mean IGF-I levels differed only minutely beyond the age of 55 years. The analysis of mean IGF-I levels across all age groups revealed lower levels for homozygous carriers of the FTO risk allele (Table 2a ). This association was more pronounced in subjects younger than 55 years of age (Table 2a) . Adjustment for age, gender, IGFBP3 and obesity or BMI left the association between FTO genotype and IGF-I stable. Additional adjusting for diabetes mellitus changed the coefficient of FTO only marginally, from À7.8±2.8 to À7.9±2.8 (n ¼ 2211).
To analyse the clinical relevance of the FTO effect on IGF-I levels, we classified IGF-I values into 'low' (n ¼ 143) and 'normal' or 'high' (n ¼ 3739) categories. Given the considerable age dependence of IGF-I levels, we have compiled reference values for clinical purposes derived from healthy SHIP participants. 30 Odds ratio of all SHIP participants homozygous for the rs9926289 A allele to be in the 'low' IGF-I category amounted to 1.6 and 2.0 before and after adjustments for age, gender and IGFBP3 (Table 2b ). For subjects younger than 55 years of age, homozygous carriers of the risk allele had more than twice the odds of belonging to the 'low' IGF-I level group (Table 2b) . A significant relationship between IGFBP3 levels and the alleles of rs9926289 was not found. The association between FTO and BMI (or other measures of body composition) was partially mediated by IGF-I and IGFBP3, the coefficient of the FTO rs9926289 AA genotype was diminished more than 10% in subjects younger than 55 years of age (Table 1b) .
We repeated the analyses with age cutoff points of 50 and 60 years instead of 55 years. Although the former strengthened the relationship between FTO and BMI in males, but weakened it in females, the latter showed a vice versa result compared with an age cutoff point of 55 years. In nongender-stratified analyses, for both altered cutoff points, the FTO effect on IGF-I and the mediator effect of IGF-I in the relationship between FTO and BMI were still present in younger age groups, but to a lower extent compared with the analyses presented.
Discussion
As there is, beyond a doubt, an associative role of FTO on BMI in Caucasians, in-depth (patho)physiological 
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mechanisms of the control in weight gain by FTO are largely elusive. The main findings of this study are (i) evidence of a clinically meaningful association between FTO risk alleles and lower IGF-I levels, which may spark a concept in which (ii) FTO effects on body composition are partially mediated by the GH-IGF-I axis. These results deserve a detailed discussion.
Enzymatic and molecular actions of FTO FTO is a member of the AlkB-related non-heme dioxygenase (Fe(II-)-and 2-oxoglutarate-dependent dioxygenases) superfamily of proteins. 20, [31] [32] [33] [34] These non-heme iron enzymes, which require Fe 2 þ as a cofactor and 2-oxoglutarate and dioxygen as cosubstrates, reverse alkylated DNA and RNA damages by oxidative demethylation. In vitro FTO protein had a strong preference for 3-methythymidine in singlestranded DNA and for 3-methyluracil in single-stranded RNA, although these methyl residues are uncommon in man. Another study has shown that more common motifs as 1-methyladenine and 3-methylcytosine were substrates of FTO, although with less activity. 35 A link between FTO demethylase activity and obesity was suggested by the observation that a single mutation in mouse FTO protein (Ile367Phe) lost its enzymatic action and was associated with a lean phenotype. Given that FTO belongs to the family of DNA repair enzymes, this issue could spark interest in the GH-IGF-I axis. In animal models, disordered genomic repair mechanisms cause obesity and metabolic syndromes. [36] [37] [38] [39] 
disordered DNA repair seems to be tightly linked to an inhibited GH secretion and to distinctly reduced IGF-I levels and has been implicated in mechanisms of ageing. [36] [37] [38] [39] However, linking FTO to these syndromes in the absence of experimental evidence is entirely notional. A recent genetic study in man reported circumstantial evidence that DNA methylation controlled appetite. 40 In detail, epistatic interaction between the risk allele of FTO, alleles of the leptin receptor and alleles of DNMT3B (DNA (cytosine-5-)-methyltransferase 3b) regulated postprandial responses in hunger and satiety. It is obvious to speculate that DNMT3B and FTO have a role in DNA methylation/ demethylation. It is noteworthy that the crystal structure of the FTO protein was recently elucidated. 32 As FTO closely resembled other AlkB proteins, specific features were established; for instance, an extra loop in the structure. The authors suspected that single-stranded RNAFand not DNAFis the primary substrate of FTO. Thus, specific demethylation of 3-methyluracil could affect the half-life or specific functions of target RNAs by FTO. 32 Eventually, this mechanism could create a new principle in cell signalling. So far, it remains impossible to predict the physiological substrates of FTO.
FTO and body mass index
As already referred to in the introductory section of this report, FTO is the strongest common genetic variation associated with BMI and obesity. [2] [3] [4] [5] [6] We could confirm the association of the FTO rs9926289 A allele with BMI and body weight for SHIP, which comprises a German population with high prevalence of overweight and obesity. [2] [3] [4] [5] [6] These findings are restricted essentially to men and women younger than 55 years of age, a life-course effect of FTO reported repeatedly. 3, [22] [23] [24] Obviously, mean gains in weight and BMI mediated by FTO are most dynamic in younger and middleage spans of life, periods that are often disease free. We hypothesized on the biological rationale of this effect and we identified the GH-IGF-I axis as a possible candidate.
Role of FTO in the hypothalamus
Although FTO transcripts are widely expressed, all reports agree that highest levels are found in the brain with the highest abundance in the hypothalamus. 3, 14, [16] [17] [18] Refined in situ hybridization studies detected prominent expression levels in regions that are critically involved in energy balance control, such as the arcuate, paraventricular, dorsomedial and ventromedial nuclei. 20 High hypothalamic FTO transcript levelsFagain with high local abundance in the arcuate nucleusFhave also been reported in animal models. [16] [17] [18] 41 Tung et al. showed that fasting reduced FTO levels in the arcuate nucleus, whereas a high-fat diet resulted in a 2.5-fold increase. 18 Manipulating FTO in the arcuate nucleus by stereotactic injections altered food intake, but did not affect transcription of gene in the arcuate nucleus classically associated with food intake, such as agouti-related protein homologue, proopiomelanocortin and neuropeptide Y. 18 However, the transcription of Stat3 was distinctly modified by the FTO microinjection. Stat3 is a signalling molecule critical for leptin receptor signalling, 18 but is also implicated in GH-releasing hormone receptor signalling. The coefficient of the FTO risk allele (recessive model) was successively adjusted for age (5-year age groups) and gender, IGFBP3 and obesity. The results remained essentially the same when body mass index instead of obesity was included in the model (coefficient: À7.9 ± 2.8; P ¼ 0.004 for subjects o55 years of age). If pregnant women and individuals with cancer were omitted, this did not change the effect.
42
b The odds ratio of the FTO risk allele (recessive model) was successively adjusted for age (5-year age groups) and gender, IGFBP3 and obesity. The results remained essentially the same when body mass index instead of obesity was included in the model (OR 2.8; 95% CI, 1.6-4.9; Po0.001 for subjects o55 years of age). If pregnant women and individuals with cancer were omitted, this did not change the effect.
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The hypophyseal secretion of GH is mainly regulated by three hypothalamic peptides that are secreted into the pituitary portal blood: GH-releasing hormone, somatostatin and ghrelin. The arcuate nucleus is the major origin of GH-releasing hormone. 43, 44 Ghrelin, an appetite-stimulating circulating hormone from the stomach and intestine, is a potent stimulator of pituitary GH secretion. 45 Ghrelin is also locally produced in the arcuate nucleus. 44 Given the coincidence of high FTO expression levels in hypothalamic areas that control GHFand thus IGF-IF secretion, a potential role of FTO in GH regulation remains to be established. Although the available studies on hypothalamic FTO transcript regulation in animals revealed discrepant details, they conclusively showed that starvation actually affected hypothalamic FTO expression. 17, 20, 41 There is even circumstantial evidence that GH-releasing hormone levels in the hypothalamus are negatively correlated with FTO levels. 41 It has long been established that fasting in man enhances GH secretion and affects GH release rhythms, which could hint at common mechanisms 46, 47 linking starvationdependent FTO expression and GH release. However, detailed experimental evidence remains to be established.
The GH-IGF-I axis and FTO The measurement of GH itself is not suitable for epidemiological studies because of its pulsatile release pattern. Therefore, quantification of serum IGF-I levels is widely used for the assessment of the GH-IGF-I axis, both in clinical and experimental medicine. 48, 49 Our data showed that age-and gender-adjusted serum IGF-I levels are significantly lower in homozygous carriers of the FTO rs9926289 A allele. Moreover, when we analysed clinically relevant 'low' IGF-I levels, we detected odds ratios for participants homozygous for the rs9926289A allele in the range of 1.6-2.0. Numerous studies reveal a strong genetic basis for IGF-I level. A longitudinal study followed up over a period of 20 years demonstrated in a set of healthy individuals a marked dissociation in individual IGF-I serum level, which, in some individuals, never overlap. 50 Studies in a large Swedish cohort of 248 twins revealed a relative genetic influence of 63% for IGF-I, clearly higher than that observed in the same study for interlinked factors such as insulin (48%) or IGFBP1 (36%). 51 More importantly, the comparison between monozygotic and dizygotic twins, as well as the influence of environmental factors evaluated by twins reared apart or together, clearly supported a dominant genetic influence with a much higher correlation of IGF-I levels in monozygotic compared with dizygotic twins and little influence of the environment. FTO may constitute such a genetic factor for the homeostasis of IGF-I.
IGF-I and obesity
Obesity has been associated with decreasing IGF-I levels. 52, 53 The apparent discrepancy in the results showing decreased or unchanged IGF-I levels in obesity was recently resolved by a large study of more than 6000 subjects over the whole range of BMI. The DETECT study supported a biphasic relation of IGF-I and BMI. 54 Both, a BMI of less than 20 or higher than 35 kg m
À2
, were associated with a lower serum IGF-I level than a BMI between 20 and 35 kg m
. The waistto-hip ratio in this cohort was negatively correlated to IGF-I, supporting an influence of visceral fat.
In our study, adjustment for obesity or BMI did not suspend the association of FTO variants with IGF-I levels. Solely in older and commonly obese individuals was the association of FTO variants with IGF-I levels no longer detectable. However, this observation does not contradict a scenario in which reduced IGF-I levels in association with the FTO risk alleles contribute to an increase in BMI during dynamic phases of weight gain, even in preadipose states.
FTO, IGF-I morbidity and mortality Accumulating evidence suggests that IGF-I is an independent risk factor for mortality. 55, 56 For SHIP, inverse associations between IGF-I or IGFBP3 levels and mortality from all causes, CVD or cancer in men, and between IGFBP3 and all-cause mortality in women, were found. 57 Interestingly, for FTO, reports exist that the increase in mortality cannot be explained solely by its FTO effect on obesity and diabetes. 58, 59 In a cohort of Danish men, the A allele of FTO had an effect on mortality similar to that of smoking. Adjustment for fatness covariates attenuated the association only slightly. 59 This effect was due to all-cause mortality and particularly due to diseases of the nervous system. 59 Recently, another group reported on the association between the risk allele of FTO and reduced brain volume in the healthy elderly. 60 It is tempting to speculate whether IGF-I could be the mediator between FTO risk allele and increased morbidity and mortality.
Conclusion
In conclusion, we have provided evidence from an epidemiological survey that FTO risk variants are related to an increased BMI. Moreover, the FTO risk alleles were associated with lower IGF-I levels independently of obesity or IGFBP3. FTO is expressed in the brain in hypothalamic regions that govern the GHFIGF-I axis. Starvation affects FTO transcript levels in these brain nuclei. The genetic mechanisms associated with FTO risk alleles comprise, most likely, an altered FTO transcription. FTO itself is an enzyme involved in RNA or DNA repair. It is unclear whether FTOFas other enzymes in this familyFexhibits sensory actions that are translated into RNA or DNA modifications. Interestingly, altered DNA repair has a strong effect on IGF1 serum levels. Although these pieces may fit into a mechanistic scheme, the mutual interactions and the elucidation of causal relationships await further experimental research to supplement the epidemiological evidence presented here.
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